Nghiem Van T, Davies Kalatu R, Beck J Robert, Follen Michele, Cantor Scott B
Center for Health Promotion and Prevention Research, The University of Texas School of Public Health, Houston, Texas. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):807-14. doi: 10.1158/1055-9965.EPI-15-1044. Epub 2016 Feb 29.
See-and-treat using loop electrosurgical excision procedure (LEEP) has been recommended as an alternative in managing high-grade cervical squamous intraepithelial lesions, but existing literature lacks evidence of the strategy's cost-effectiveness. We evaluated the overtreatment and cost-effectiveness of the see-and-treat strategy compared with usual care.
We modeled a hypothetical cohort of 40-year-old females who had not been screened for cervical cancer and followed them through their lifetimes using a Markov model. From a U.S. health-system perspective, the analysis was conducted in 2012 dollars and measured effectiveness in quality-adjusted life-years (QALY). We estimated incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $50,000/QALY. The robustness of the see-and-treat strategy's cost-effectiveness and its overtreatment rates were further examined in various sensitivity analyses.
In the base-case, the see-and-treat strategy yielded an ICER of $70,774/QALY compared with usual care. For most scenarios in the deterministic sensitivity analysis, this strategy had ICERs larger than $50,000/QALY, and its cost-effectiveness was sensitive to the disutility of LEEP treatment and biopsy-directed treatment adherence under usual care. Probabilistic sensitivity analysis showed that the see-and-treat strategy had a 50.1% chance to be cost-effective. It had an average overtreatment rate of 7.1% and a 78.8% chance to have its overtreatment rate lower than the 10% threshold.
The see-and-treat strategy induced an acceptable overtreatment rate. Its cost-effectiveness, compared with usual care, was indiscriminating at the chosen willingness-to-pay threshold but much improved when the threshold increased.
The see-and-treat strategy was reasonable for particular settings, that is, those with low treatment adherence. Cancer Epidemiol Biomarkers Prev; 25(5); 807-14. ©2016 AACR.
采用环形电切术(LEEP)进行即诊即治被推荐为高级别宫颈鳞状上皮内病变管理的一种替代方法,但现有文献缺乏该策略成本效益的证据。我们评估了即诊即治策略与常规治疗相比的过度治疗情况及成本效益。
我们构建了一个未进行过宫颈癌筛查的40岁女性的假设队列,并使用马尔可夫模型对她们进行终生随访。从美国卫生系统的角度,分析以2012年美元进行,并以质量调整生命年(QALY)衡量有效性。我们使用每QALY支付意愿阈值50,000美元来估计增量成本效益比(ICER)。在即诊即治策略成本效益及其过度治疗率的稳健性在各种敏感性分析中进一步进行了检验。
在基础病例中,与常规治疗相比,即诊即治策略产生的ICER为每QALY 70,774美元。在确定性敏感性分析的大多数情况下,该策略的ICER大于每QALY 50,000美元,并且其成本效益对LEEP治疗的负效用和常规治疗下活检导向治疗的依从性敏感。概率敏感性分析表明,即诊即治策略具有50.1%的成本效益机会。其平均过度治疗率为7.1%,并且有78.8%的机会使其过度治疗率低于10%的阈值。
即诊即治策略导致了可接受的过度治疗率。与常规治疗相比,其成本效益在所选择的支付意愿阈值下并无差异,但当阈值增加时则有很大改善。
即诊即治策略在特定环境中是合理的,即那些治疗依从性低的环境。《癌症流行病学、生物标志物与预防》;25(5);807 - 14。©2016美国癌症研究协会。